In a meta-analysis including 38 trials, Pinto et al. found no association between pancreatic cancer and the use of DPP-4 inhibitors (odds ratio 0.65; 95% CI 0.35–1.21) [29]. This evidence concerns the gene DPP4 and familial pancreatic carcinoma.